Pricing of US Private Placement of Notes
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Bridgepoint Group plc
("Bridgepoint" or the "Company")
Pricing of US Private Placement of Notes
Bridgepoint today announces that the Bridgepoint group (the "Group") has successfully priced US$430 million of US Private Placement ("USPP") notes. The USPP will be structured in 4 tranches, with maturities of 3, 5, 7 and 10 years and an average coupon of 6.17 per cent.
Proceeds from the USPP will provide the Group with additional resources to continue its strategic growth plans, and in part will be used to refinance certain ECP debt following the ECP transaction.
Formal signing of the USPP is expected to occur in the coming weeks, and issue of the USPP notes is expected to occur in Q2 2024, subject to the closing of the ECP transaction and the satisfaction of customary conditions.
Bridgepoint believes that the transaction highlights US investors' confidence in the Group's credit quality well as in its growth strategy over the longer term.
ENQUIRIES
Bridgepoint
|
Analysts and investors Adam Key +44 7833 748010
|
Media Christian Jones / James Murray christian.jones@bridgepoint.eu +44 20 7034 3500 |
FGS Global (Public Relations Adviser to Bridgepoint)
Charles O'Brien / +44 20 7251 3801 / +44 7825 043 656
Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233
Legal Entity Identifier (LEI): 213800KFNMVI8PDZX472
Cautionary Statement
This announcement should not be construed as an investment recommendation nor does it constitute an offer to sell or the solicitation of any offer to buy interests in any security. Offers may only be made at the time a qualified offeree receives the related confidential information memorandum for a specific investment describing the offering and executes a related subscription agreement. Any interests in securities of Bridgepoint or any of its subsidiaries shall not be offered or sold in any jurisdiction in which such an offer, solicitation or sale would be unlawful until the requirements of the laws of such jurisdiction have been satisfied. Any investment decisions with respect to any securities should be made solely based on the information contained in the respective final offering documentation.
Information Regarding Forward-Looking Statements
The information contained in this announcement may contain forward-looking statements that reflect Bridgepoint's current views with respect to, among other things, future financial and business performance events, strategies and expectations. Bridgepoint generally identifies forward-looking statements by terminology such as "outlook," "believe," "expect," "potential," "continue," "may," "will," "should," "seeks," "approximately," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of those words or other comparable words. Any forward-looking statements contained in this announcement are based upon historical performance and market information, and on Bridgepoint's current plans, estimates and expectations. The inclusion of this forward-looking information should not be regarded as a representation by Bridgepoint or any other person that the future plans, estimates or expectations contemplated by Bridgepoint will be achieved. Such forward-looking statements are subject to various risks and uncertainties, as well as assumptions relating to Bridgepoint's operations, financial results, financial condition, business prospects, growth strategy and liquidity. If one or more of these or other risks or uncertainties materialize, or if underlying assumptions prove to be incorrect, Bridgepoint's actual results may vary materially from those indicated in these statements. Any forward-looking statements, views, and opinions contained in this announcement are current as of the date of this announcement but are subject to change. Except as required by applicable law, Bridgepoint does not undertake any obligation to update or review any forward-looking statement, views, and opinions, whether as a result of new information, future developments or otherwise.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Johnson Matthey
- 2 hours ago Galliford Try
- 2 hours ago Galliford Try
- 2 hours ago Centrica
- 3 hours ago Smith & Nephew